A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT
- Resource Type
- Authors
- Holger Hebart; Olle Ringdén; Lena Klingspor; N Stenger; Hannes Wandt; J Tollemar; H. Einsele; H J Dornbusch; Per Ljungman; C Meisner; K Schaefer-Eckart; T Mayer; Jay S. Loeffler; C Engel; T Klingebiel
- Source
- Bone Marrow Transplantation. 43:553-561
- Subject
- Adult
Male
medicine.medical_specialty
Adolescent
Polymerase Chain Reaction
Gastroenterology
Group B
law.invention
Pharmacotherapy
Randomized controlled trial
law
Amphotericin B
Internal medicine
medicine
Humans
Transplantation, Homologous
Child
Mycosis
Survival analysis
Aged
Transplantation
business.industry
Infant
Hematology
Middle Aged
medicine.disease
Survival Analysis
Surgery
Mycoses
Child, Preschool
Liposomes
Female
business
Febrile neutropenia
Stem Cell Transplantation
medicine.drug
- Language
- ISSN
- 1476-5365
0268-3369
We compared the efficacy and safety of empirical plus PCR-based vs empirical liposomal amphotericin B treatment after Allo-SCT. Allo-SCT recipients were randomized to receive either PCR-based preemptive therapy (group A; n=198) or empirical antifungal therapy (group B; n=211) with liposomal amphotericin B. In group A, therapy was started after one positive PCR result or after 120 h of febrile neutropenia refractory to broad-spectrum antibacterial therapy. In group B, liposomal amphotericin B was started after 120 h of refractory febrile neutropenia. Demographic and clinical characteristics were well balanced. A total of 112 (57.1%) patients in group A and 76 (36.7%) patients in group B received antifungal therapy (P